VIDEO: Dr. William Gradishar says tools to define patients for targeted therapy are on the horizon

SAN ANTONIO – Clinicians can expect tools to appear in the clinic in the very near future that will help define who will benefit from targeted therapy and who can get by with less therapy, Dr. William J. Gradishar asserted at the San Antonio Breast Cancer Symposium.

In particular, Dr. Gradishar cited BOLERO-2 and BELLE-2 results as evidence that evaluating the tumors of patients can lead to identifying those who will obtain benefit from targeted agents.

In a video interview, Dr. Gradishar also outlined where things stand on extended therapy for HER2-positive patients, and whether the use of osteoclast inhibitors is a new standard of care.

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology at Northwestern University, Chicago.

[email protected]

SAN ANTONIO – Clinicians can expect tools to appear in the clinic in the very near future that will help define who will benefit from targeted therapy and who can get by with less therapy, Dr. William J. Gradishar asserted at the San Antonio Breast Cancer Symposium.

In particular, Dr. Gradishar cited BOLERO-2 and BELLE-2 results as evidence that evaluating the tumors of patients can lead to identifying those who will obtain benefit from targeted agents.

In a video interview, Dr. Gradishar also outlined where things stand on extended therapy for HER2-positive patients, and whether the use of osteoclast inhibitors is a new standard of care.

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology at Northwestern University, Chicago.

[email protected]

SAN ANTONIO – Clinicians can expect tools to appear in the clinic in the very near future that will help define who will benefit from targeted therapy and who can get by with less therapy, Dr. William J. Gradishar asserted at the San Antonio Breast Cancer Symposium.

In particular, Dr. Gradishar cited BOLERO-2 and BELLE-2 results as evidence that evaluating the tumors of patients can lead to identifying those who will obtain benefit from targeted agents.

In a video interview, Dr. Gradishar also outlined where things stand on extended therapy for HER2-positive patients, and whether the use of osteoclast inhibitors is a new standard of care.

Dr. Gradishar is the Betsy Bramsen Professor of Breast Oncology at Northwestern University, Chicago.

[email protected]